Document is current
Any future updates will be listed below
-
Authors
Becattini, Simone https://orcid.org/0000-0001-5985-0403
Littmann, Eric R.
Seok, Ruth
Amoretti, Luigi
Fontana, Emily
Wright, Roberta
Gjonbalaj, Mergim
Leiner, Ingrid M.
Plitas, George
Hohl, Tobias M. https://orcid.org/0000-0002-9097-5412
Pamer, Eric G.
-
Funding
Funding for this research was provided by:
Cancer Research Institute (49679)
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (2EZP3_15908)
U.S. Department of Health & Human Services | National Institutes of Health (P30 CA008748, AI042135)
U.S. Department of Health & Human Services | National Institutes of Health
- License Information
-
More Information
Article History
Received: 6 September 2019
Accepted: 4 August 2020
First Online: 8 September 2020
Competing interests
: E.G.P. has received speaker honoraria from Bristol Myers Squibb, Celgene, Seres Therapeutics, MedImmune, Novartis and Ferring Pharmaceuticals and is an inventor on patent application # WPO2015179437A1, entitled “Methods and compositions for reducing <i>Clostridium difficile</i> infection” and #WO2017091753A1, entitled “Methods and compositions for reducing vancomycin-resistant enterococci infection or colonization” and holds patents that receive royalties from Seres Therapeutics, Inc. All other authors declare no competing interests.
